Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. ROIV
2. HUVR:IN
3. ASML
4. NVS
5. TTE
6. ANET
7. NKE
8. BE
9. PANW
10. CL

Go back to Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
INSMED (NASDAQ: INSM) Delayed: 126.29 --0 (-0%)
Previous Close $126.29    52 Week High $19.30 
Open $126.29    52 Week Low $9.02 
Day High $126.29    P/E N/A 
Day Low $126.29    EPS $-1.69 
Volume 552